SmallCaps
ASX:PEBPharmaceuticals, Biotechnology & Life SciencesBiotechnology

Pacific Edge Ltd

$0.215
$0.005 (2.27%)
Day Range
$0.215 – $0.215
Volume
10.00K
Avg Volume (10D)
831.68K
Market Cap
$267.00M

Price Chart

OHLC · volume · moving averages

$0.215+$0.025 (+13.16%)over 6M
Hi$0.265Lo$0.140
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.215
Previous Close
$0.220
Day High
$0.215
Day Low
$0.215

Valuation

Fundamental multiples

Market Cap
267.00M
Shares Outstanding
1.24B
Price to Book
24.94

Trading Activity

Volume & order book

Volume
10.00K
Value Traded
2.15K
Bid
$0.210 × 60,000
Ask
$0.215 × 17,300

Performance

Returns across timeframes

1 Day
1.96%
5 Day
0.00%
13 Week
-3.70%
52 Week
142.99%
YTD
40.54%

— From the desk

Latest News

Pacific Edge Test Volumes Rise 2.7% in Q4 on Payer Expansion
Biotechnology

Pacific Edge Test Volumes Rise 2.7% in Q4 on Payer Expansion

Pacific Edge (PEB) Q4 test volumes rise 2.7% on payer expansion; eyes Medicare LCD draft by Sept 2026 as coverage broadens, signaling regulatory momentum.

Pacific Edge’s Cxbladder Triage biomarker test recognised as standard of care in AUA guideline update
Biotechnology

Pacific Edge’s Cxbladder Triage biomarker test recognised as standard of care in AUA guideline update

New Zealand-based cancer diagnostics company Pacific Edge (ASX: PEB) has had its Cxbladder Triage test included as a standard of care by the American Urological Association (AUA). In a major amendment to the 2020 AUA microhematuria guideline, the AUA panel has incorporated language for the use of urine-based biomarkers for intermediate-risk patients. Most notably, it […]

Medtech firms assessing impact of proposed FDA regulation changes
Biotechnology

Medtech firms assessing impact of proposed FDA regulation changes

Local medtech companies are rushing to assess proposed new US Food and Drug Administration (FDA) rule changes that seek to have laboratory developed tests (LDTs) regulated as medical devices under the US Federal Food, Drug, and Cosmetic Act. The proposed changes are being aggressively opposed by numerous associations including the Coalition for 21st Century Medicine […]

Market wrap: good news on jobs turns to bad news for shares
Hot Topics

Market wrap: good news on jobs turns to bad news for shares

Once again, the Australian share market turned good economic news into a bad share performance as the ASX 200 index slumped to a three-month low of just 7042.3 points. Hot US jobs figures from ADP Research found that employers added 497,000 jobs in June – nearly double what was expected – driving most traders to […]